OBJECTIVES: To examine the association of cognitive impairment with platelet activation and reactive oxygen species and total homocysteine levels; and to assess the biochemical efficacy of treatment with aspirin and vitamin supplements in people at high risk of dementia. SUBJECTS:People with dementia or mild cognitive impairment. DESIGN AND INTERVENTION: In a 2 x 2 x 2 factorial design trial, 149 people at high-risk of dementia were randomized to receive either low-dose aspirin (81 mg) or placebo; and folic acid (2 mg) plus vitamin B12 (1 mg) or placebo; and vitamins E (500 mg) plus C (200 mg) or placebo. Participants were seen twice before and once after 12 weeks of treatment. MAIN OUTCOME MEASURES: At each visit, participants had their cognitive function assessed and had blood collected for homocysteine, folate and vitamin B12 determination and urine collected for markers of platelet activation (11-dehydro-thromboxane B2) and reactive oxygen species (8-epi-PGF2 alpha). RESULTS: Prior to treatment, cognitive function was inversely related with homocysteine and with urinary thromboxane and isoprostane, and these associations were independent of age. Aspirin was associated with a median reduction in 11-dehydrothromboxane B2 of 73% (P < 0.001). B-vitamins lowered plasma homocysteine concentration by 30% (P < 0.0001) and antioxidant vitamins lowered isoprostane excretion by 26% (P < 0.1). No effect of treatment on cognitive function was detected. CONCLUSIONS:Aspirin and B-vitamins were effective in reducing biochemical factors associated with cognitive impairment in people at risk of dementia. Large-scale trials are now required to assess the relevance of aspirin and B-vitamins for the maintenance of cognitive function in people at risk of dementia.
RCT Entities:
OBJECTIVES: To examine the association of cognitive impairment with platelet activation and reactive oxygen species and total homocysteine levels; and to assess the biochemical efficacy of treatment with aspirin and vitamin supplements in people at high risk of dementia. SUBJECTS:People with dementia or mild cognitive impairment. DESIGN AND INTERVENTION: In a 2 x 2 x 2 factorial design trial, 149 people at high-risk of dementia were randomized to receive either low-dose aspirin (81 mg) or placebo; and folic acid (2 mg) plus vitamin B12 (1 mg) or placebo; and vitamins E (500 mg) plus C (200 mg) or placebo. Participants were seen twice before and once after 12 weeks of treatment. MAIN OUTCOME MEASURES: At each visit, participants had their cognitive function assessed and had blood collected for homocysteine, folate and vitamin B12 determination and urine collected for markers of platelet activation (11-dehydro-thromboxane B2) and reactive oxygen species (8-epi-PGF2 alpha). RESULTS: Prior to treatment, cognitive function was inversely related with homocysteine and with urinary thromboxane and isoprostane, and these associations were independent of age. Aspirin was associated with a median reduction in 11-dehydrothromboxane B2 of 73% (P < 0.001). B-vitamins lowered plasma homocysteine concentration by 30% (P < 0.0001) and antioxidant vitamins lowered isoprostane excretion by 26% (P < 0.1). No effect of treatment on cognitive function was detected. CONCLUSIONS:Aspirin and B-vitamins were effective in reducing biochemical factors associated with cognitive impairment in people at risk of dementia. Large-scale trials are now required to assess the relevance of aspirin and B-vitamins for the maintenance of cognitive function in people at risk of dementia.
Authors: Martha Clare Morris; Denis A Evans; Julie A Schneider; Christine C Tangney; Julia L Bienias; Neelum T Aggarwal Journal: J Alzheimers Dis Date: 2006-08 Impact factor: 4.472
Authors: Annelies C Ham; Anke W Enneman; Suzanne C van Dijk; Sadaf Oliai Araghi; Karin M A Swart; Evelien Sohl; Janneke P van Wijngaarden; Nikita L van der Zwaluw; Elske M Brouwer-Brolsma; Rosalie A M Dhonukshe-Rutten; Natasja M van Schoor; Tischa J M van der Cammen; M Carola Zillikens; Robert de Jonge; Paul Lips; Lisette C P G M de Groot; Joyce B J van Meurs; André G Uitterlinden; Renger F Witkamp; Bruno H C Stricker; Nathalie van der Velde Journal: Drugs Aging Date: 2014-08 Impact factor: 3.923
Authors: Nicolas Farina; Mokhtar Gad El Kareem Nasr Isaac; Annalie R Clark; Jennifer Rusted; Naji Tabet Journal: Cochrane Database Syst Rev Date: 2012-11-14
Authors: M Manders; L C P G M De Groot; W H L Hoefnagels; R A M Dhonukshe-Rutten; W Wouters-Wesseling; A J M J Mulders; W A Van Staveren Journal: J Nutr Health Aging Date: 2009-11 Impact factor: 4.075